Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
P/S ratio for Insmed Incorporated (INSM)
P/S ratio as of 2023: 14.26
According to Insmed Incorporated's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 14.26. At the end of 2022 the company had a P/S ratio of 10.02.
P/S ratio history for Insmed Incorporated from 1999 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 14.26 |
| 2022 | 10.02 |
| 2021 | 16.20 |
| 2020 | 19.76 |
| 2019 | 14.80 |
| 2018 | 102.51 |
| 2017 | 0.00 |
| 2016 | 0.00 |
| 2015 | 0.00 |
| 2014 | 57.87 |
| 2013 | 51.71 |
| 2012 | 0.00 |
| 2011 | 16.12 |
| 2010 | 12.08 |
| 2009 | 9.44 |
| 2008 | 4.88 |
| 2007 | 12.57 |
| 2006 | 84.64 |
| 2005 | 732.99 |
| 2004 | 628.56 |
| 2003 | 704.88 |
| 2002 | 7.44 |
| 2001 | 424.21 |
| 2000 | 1059.07 |
| 1999 | 78.50 |